Trials / Recruiting
RecruitingNCT06999590
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrixlike Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Tiger Biosciences, LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study it to evaluate several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
Detailed description
To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing pressure ulcers with multiple CAMPs plus SOC versus matched SOC controls (mSOC) over 20 weeks using a modified platform trial design. The initial plan is to evaluate two CAMPs; however, the modified platform design permits the inclusion of additional CAMPs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | ACApatch™ | Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first. |
| OTHER | caregraFT™ | Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first. |
| OTHER | Standard of Care | Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance) until ulcer closure, or a maximum of 20 weeks, whichever occurs first. |
Timeline
- Start date
- 2025-05-20
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2025-05-31
- Last updated
- 2025-06-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06999590. Inclusion in this directory is not an endorsement.